Close
  • Home

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

Funding

Approval  ·  Weekly Digest 01 Feb to 07 Feb 2025
Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU

Weekly Digest – February 2025 Weekly Digest – February 2025 31 Jan 2025: Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU The FDA approved a label expansion for […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest 01 Feb to 07 Feb 2025
Pyxis Oncology initiates new PYX-201 combination trial and initiates cohort expansions of ongoing monotherapy trial

Weekly Digest – February 2025 Weekly Digest – February 2025 04 Feb 2025: Pyxis Oncology initiates new PYX-201 combination trial and initiates cohort expansions of ongoing monotherapy trial Pyxis Oncology announced progress in its clinical program for PYX-201, an ADC […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest 01 Feb to 07 Feb 2025
Pfizer axes B7-H4 ADC, triggering $1B impairment charge as blockbuster vision evaporates

Weekly Digest – February 2025 Weekly Digest – February 2025 04 Feb 2025: Pfizer axes B7-H4 ADC, triggering $1B impairment charge as blockbuster vision evaporates Pfizer has discontinued the development of its B7-H4-directed ADC, B7H4V, resulting in a $1 billion […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest 01 Feb to 07 Feb 2025
Merck announces phase 3 waveLINE-010 trial initiation evaluating Zilovertamab Vedotin, an investigational antibody-drug conjugate, for the treatment of patients with previously untreated diffuse large B-cell lymphoma

Weekly Digest – February 2025 Weekly Digest – February 2025 06 Feb 2025: Merck announces phase 3 waveLINE-010 trial initiation evaluating Zilovertamab Vedotin, an investigational antibody-drug conjugate, for the treatment of patients with previously untreated diffuse large B-cell lymphoma Merck […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest 01 Feb to 07 Feb 2025
Anti-HER2 bispecific ADC JSKN003 received approval to initiate a phase 3 clinical study for the treatment of HER2-positive breast cancer

Weekly Digest – February 2025 Weekly Digest – February 2025 06 Feb 2025: Anti-HER2 bispecific ADC JSKN003 received approval to initiate a phase 3 clinical study for the treatment of HER2-positive breast cancer Alphamab oncology and CSPC pharmaceutical received NMPA […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest 25 Jan to 31 Jan
Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic Breast Cancer following disease progression after one or more endocrine therapies

Weekly Digest – January 2025 Weekly Digest – January 2025 27 Jan 2025: Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic Breast Cancer following disease progression after one or more endocrine therapies  […]

by Sandhya Ramalingam

Continue Reading
Clinical  ·  Weekly Digest 25 Jan to 31 Jan
TROPION-Lung12 phase 3 trial initiated evaluating DATROWAY as part of adjuvant regimen for patients with early-stage Non-Small Cell Lung Cancer at high risk of relapse

Weekly Digest – January 2025 Weekly Digest – January 2025 30 Jan 2025: TROPION-Lung12 phase 3 trial initiated evaluating DATROWAY as part of adjuvant regimen for patients with early-stage Non-Small Cell Lung Cancer at high risk of relapse The TROPION-Lung12 […]

by Sandhya Ramalingam

Continue Reading
Clinical  ·  Weekly Digest 25 Jan to 31 Jan
Tubulis Announces First Patient Dosed in Phase I/IIa Trial Evaluating ADC TUB-030 in Advanced Solid Tumors

Weekly Digest – January 2025 Weekly Digest – January 2025 30 Jan 2025: Tubulis announces first patient dosed in Phase 1/2a trial evaluating ADC TUB-030 in advanced solid tumors TUB-030 entered clinical evaluation with the first patient dosed in the […]

by Sandhya Ramalingam

Continue Reading
Clinical  ·  Weekly Digest 25 Jan to 31 Jan
Vincerx Pharma, Inc. and Oqory, Inc. highlight promising data for Oqory’s TROP2 ADC , OQY-3258

Weekly Digest – January 2025 Weekly Digest – January 2025 29 Jan 2025: Vincerx Pharma and Oqory highlight promising data for Oqory’s TROP2 ADC, OQY-3258   Vincerx Pharma and Oqory highlighted Phase 1a/1b data for OQY-3258  It proposed a merger to advance […]

by Sandhya Ramalingam

Continue Reading
Clinical  ·  Weekly Digest 25 Jan to 31 Jan
Innate Pharma announces first patient dosed in phase 1 study of its Nectin-4 targeting antibody drug conjugate IPH4502 in selected advanced solid tumors

Weekly Digest – January 2025 Weekly Digest – January 2025 27 Jan 2025: Innate Pharma announces first patient dosed in phase 1 study of its Nectin-4 targeting antibody drug conjugate IPH4502 in selected advanced solid tumors Innate Pharma began a […]

by Sandhya Ramalingam

Continue Reading
« First‹ Previous535455565758596061Next ›Last »
Page 57 of 63


Contact:

  info@ciscientists.com

 +1-908-212-7484

Optimal Dose

For a subscription, please provide your email id